In August 2011, the National Lung Screening Trial (NLST) investigators published their results: screening with low-dose computed tomography (LDCT) reduces mortality from lung cancer among heavy smokers.1 For some, these results were evidence enough to begin LDCT screening programs. Others2 more closely examined the total evidence about the value of lung cancer screening, that is, the extent to which the benefits justify the harms and costs.3